Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas

Tumori

Volumn 85, Issue 1, 1999, Pages 35-40

  Alò, Piero L ^a   Visca, Paolo ^b   Trombetta, Giorgio ^a   Mangoni, Antonella ^a   Lenti, Luisa ^a   Monaco, Simona ^a   Botti, Claudio ^b   Serpieri, Daniele Eleuteri ^a   Di Tondo, Ugo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast carcinoma; Fatty acid synthase; Prognosis

Indexed keywords

CATHEPSIN D; ESTROGEN RECEPTOR; FATTY ACID SYNTHASE; ONCOPROTEIN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER STAGING; DISCRIMINANT ANALYSIS; EARLY CANCER; FATTY ACID SYNTHESIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PLOIDY; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

EID: 0033009256     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169908500108     Document Type: Article

References (46)

1. Anderson T.J.: C-erbB-2 oncogene in breast cancer: the right target or a decoy? Hum. Pathol., 23: 971-973, 1992.
2. Armas O.A., Gerald W.L., Lesser M.L., Arroyo C.D., Norton L., Rosen P.P.: Immunohistochemical detection of cathepsin D in T2N0M0 breast carcinoma. Am. J. Surg. Pathol., 18/2: 158-166, 1994.
3. Bacus S.S., Ruby S.G., Weinberg D.S., Chin D., Ortiz R., Bacus J.W.: HER-2/oncogene expression and proliferation in breast cancers. Am. J. Pathol., 137: 103-111, 1990.
4. Bennet S.: Log logistic regression models for survival data. Appl. Stat., 32: 165-171, 1983.
5. Brouillet J.P., Theillet C., Maudelonde T., Defrenne A., Simony-Lafontaine J., Sertour J., Pujol H., Jeanteur P., Rochefort H.: Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erbB-2 and int-2 oncogene amplification and node invasiveness. Eur. J. Cancer, 26: 437-441, 1990.
6. Cardiff R.D.: Cathepsin D and breast cancer: useful? Hum. Pathol., 25: 847-848, 1994.
7. Chalbos D., Joyeux C., Escot T., Galter F., Rochefort H.: Progestin-induced fatty acid synthetase in breast cancer. Ann. N.Y. Acad. Sci., 595: 67-73, 1990.
8. Chu K.C., Tarone R.E., Kessler L.G., Ries L.A., Hankey B.F., Miller B.A., Edwards B.K.: Recent trends in US breast cancer incidence, survival and mortality. J. Natl. Cancer Inst., 18; 88: 1791-1793, 1996.
9. Clemente C.G., Boracchi P., Andreola S., Del Vecchio M., Veronesi U., Rilke F.O.: Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer, 69: 1396-1403, 1992.
10. Cooke T., Shields R., George D., Maynard P., Griffith S.K.: Oestrogen receptors and prognosis in early breast cancer. Lancet, 1: 995-997, 1979.
11. Di Fiore P.P., Pierce J.H., Kraus M.H., Segatto O., King C.R., Aaronson S.A.: C-erbB-2 is a potent oncogene when over-expressed in NIH/3T3 cells. Science, 237: 178-182, 1987.
12. Dixon W.J.: BMDP statistical software. University of California Press, Berkeley, 1985.
13. Domagala W., Striker G., Szadowska A., Dukowicz A., Weber K., Osborn M.: Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry: no correlation with survival at 5 years. Am. J. Pathol., 141: 1003-1012, 1992.
14. Dressier L.G., Eudey L., Gray R., Tormey D.C., McGuire W.L., Gilchrist K.W., Clark G.M., Osborne C.K., Mansour E.G., Abeloff M.D.: Preliminary analysis of the impact of DNA flow cytometry measurement to predict time to recurrence in the intergroups (INT 011) node negative clinical trials: an Eastern Cooperative Oncology Group Study. J. Natl. Cancer Inst. Monogr., 11: 167-172, 1992.
15. Dressler LG.: Are DNA flow cytometry measurements providing useful information in the management of node negative breast cancer patients? Cancer Invest., 10: 477-486, 1993.
16. Epstein J.I, Carmichael M., Partin A.W.: OA519 (fatty acid synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate. Urology, 45: 81-86, 1995.
17. Feig S.A.: Mammographic screening of women aged 40-44 years. Benefit, risk and cost consideration. Cancer, 15 (suppl. 10): 2097-2106, 1995.
18. Fisher B., Gunduz N., Costantino J., Fisher E.R., Redmond C., Mamounas E.P, Sideritz R.: DNA flow cytometric analysis of primary operable breast cancer: relation of ploidy and S-phase fraction to prognosis of patients in NSABP B-04. Cancer, 68: 1465-1475, 1991.
19. Gasparini G, Gullick W.J., Bevilacqua P., Richard C., Sansbury J., Meli S., Baracchi P., Testolin A., La Malfa G., Pozza F.: Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J. Clin. Oncol., 10: 686-695, 1992.
20. Gasparini G., Pozza F., Harris A.C.: Evaluating the potential useful and predictive indicators in node-negative breast cancer patients. J. Natl. Cancer Inst., 85: 1206-1219, 1993.
21. Gasparini G., Weidner N., Bevilacqua P., Maluta S., Della Palma P., Caffo O., Barbareschi M., Boracchi P., Marubini E., Pozza F.: Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J. Clin. Oncol., 12: 454-466, 1994.
22. Gillett C.E., Happerfield L.C.: Breast cancer: from clinic to laboratory. Br. J. Biomed. Sci., 54: 47-56, 1997.
23. Haerslev T., Jacobsen G.K.: C-erbB-2 is not an independent prognostic parameter in primary breast carcinoma. An immunohistochemical study. APMIS, 102: 612-622, 1994.
24. Hardman W., Gansler T., Schaffel S., Henningar R.A.: OA519 immunostaining portends poor prognosis in ovarian cancer. Mod. Pathol., 8: 90A, 1995.
25. Hedley D.W., Clark G.M., Cornelisse C.J., Killander D., Kute T., Merkel D.: Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry, 14: 482-485, 1993.
26. Helin H.J., Helle M.J., Helin M.L., Isola J.J.: Immunocytochemical detection of estrogen and progesterone receptors in 124 human breast cancers. Am. J. Clin. Pathol., 90: 137-142, 1988.
27. Hsu S.M., Raine L., Fanger H.: The use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabelled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-580, 1981.
28. Kuhajda F.P., Katumuluwa A.I., Pasternack G.R.: Expression of haptoglobin related protein and its potential role as a tumor antigen. Proc. Natl. Acad. Sci. USA, 86: 1188-1192, 1989.
29. Kuhajda F.P., Piantadosi S., Pasternack G.R.: Haptoglobin-related protein (Hpr). Epitopes in breast cancer as a predictor of recurrence of disease. N. Engl. J. Med., 321: 636-641, 1989.
30. Kuhajda F.P., Jenner K., Wood F.D., Hennigar R.A., Jacobs L.B, Dick J.D., Pasternack G.R.: Fatty acid synthesis. A potential target for antineoplastic therapy. Proc. Natl. Acad. Sci. USA, 91: 6379-6383, 1994.
31. Lee A.K., Lellis R.A., Silverman M.L., Heatley G.J., Wolfe H.J.: Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J. Clin. Oncol., 8: 1457-1465, 1990.
32. Lewis W.E.: Prognostic significance of flow cytometric DNA analyses in node negative breast patients. Cancer, 65: 2315-2320, 1990.
33. Mansour E.G., Ravdin P.M., Dressier L.: Prognostic factor in early breast carcinoma. Cancer, 74/1: 381-400, 1994.
34. McCann A., Derwan P.A., Johnston P.A., Gullick W.J., Carney D.N.: C-erbB-2 oncoprotein expression in primary human tumors. Cancer, 65: 88-92, 1990.
35. Osborne C.K.: Prognostic factors for breast cancer; have they met their promise? J. Clin. Oncol., 10: 679-682, 1992.
36. Page D.L, Anderson T.S.: Vessel invasion. In: Diagnostic histopathology of the breast, Page D.L., Anderson T.S. (Eds.), pp. 283-284, Churchill-Livingstone, Edinburgh, 1987.
37. Mc Carthy A.D., Hardie D.G.: Fatty acid synthase: an example of protein evolution by gene fusion. Trend. Biochem. Sci., 9: 60-63, 1984.
38. Paulauskis J.D., Sul H.S.: Hormonal regulation of mouse fatty acid synthase gene trascription in liver. J. Biol. Chem., 264: 574-577, 1989.
39. Pizer E.S., Wood F.D., Pasternack G.R., Kuhajda F.P.: Altered fatty acid biosynthesis in endometrial carcinoma. Mod. Pathol., 8: 95A, 1995.
40. Rashid A., Pizer E.S., Moga M., Milgraum L.Z., Zahurak M., Pasternak G.R., Kuhajda F.P.: Expression of fatty acid synthase in colorectal cancer. Am. J. Pathol., 150: 201-208, 1997.
41. Redston M.S., Kern S.E., Vogelstein B., Hamilton S.R.: Expression of OA519 (haptoglobin-related protein epitopes) in colorectal carcinomas: comparison with molecular genetic alteration and metastasis. Mod. Pathol., 5: 47A, 1997.
42. Rosen P.P., Oberman H.A.: Invasive carcinoma. In: Tumors of the mammary gland (3rd series), Rosen P.P., Oberman H.A. (Eds.), pp. 157-243, A.F.I.P. Washington, 1997.
43. Shurbaji M.S., Kuhajda F.P., Pasternack G.R., Thurmond T.S.: Expression of oncoantigen 519 (OA-519) in prostatic cancer is a potential prognostic indicator. Am. J. Clin. Pathol., 97: 686-691, 1992.
44. Singleton T.P., Niehans G.A., Gu F., Litz C.E., Hagen K., Qiu Q., Kiang D., Strickler J.G.: Detection of c-erbB-2 activation in paraffin embedded tissue by immunohistochemistry. Hum. Pathol., 23/10: 1141-1150, 1992.
45. Sobin L.H., Wittekind C.H.: International Union Against Cancer: TNM classification of malignant tumors (5th ed.), pp. 123-130, John Wiley and Sons, Inc., 1997.
46. Thorpe S.M., Rochefort H., Garcia M., Freiss G., Christensen I.J., Khalaf S.: Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. J. Cancer Res., 49: 6008-6011, 1989.